Wegovy benefits: weight loss, heart, and liver health

Wegovy (semaglutide) is best known as a weight loss medication. But Wegovy benefits go further: It's also approved by the US Food and Drug Administration (FDA) to reduce the risk of major cardiovascular events such as heart attack and stroke in adults with heart disease who carry excess weight, and to treat a serious liver disease called MASH. It may also help lower blood pressure, though that isn't an approved use.

Here's what the research shows for each potential Wegovy benefit, and how to tell whether Wegovy might be right for you.

The benefits of Wegovy fall into four main areas: meaningful weight loss, a lower risk of heart attack and stroke, lower blood pressure, and improvement in the liver disease metabolic dysfunction-associated steatohepatitis (MASH). Three of those are official FDA approvals. Blood pressure isn't on that list, but it’s a consistent finding in the trials.

Since December 2025, Wegovy has come in two forms: a weekly injection and a daily pill. The Wegovy pill is approved for weight management and for cardiovascular risk reduction in adults. MASH remains injection-only. 

Wegovy’s approved uses have grown since its launch. It’s now approved for weight management (in adults and adolescents aged 12 and older), cardiovascular risk reduction, and MASH. For adolescents, only the injection is approved so far, and it is specifically approved for those with obesity. 

See if you qualify

In clinical trials, average weight loss ranged from about 14% on the Wegovy pill to nearly 19% on the highest-dose Wegovy injection (7.2 mg), in both cases alongside a reduced-calorie diet and increased physical activity. 

The injection has the most research behind it. In one trial of adults without diabetes who took 2.4 mg of semaglutide once weekly, the average weight loss was 14.9% of body weight over 68 weeks, compared with 2.4% on placebo. Around 86% of those taking semaglutide lost at least 5% of their body weight, against roughly 32% on placebo. 

If you started at 250 pounds, matching that trial average would mean losing around 37 pounds. 

That effect seems to hold up over time, too. In a two-year trial, participants taking semaglutide lost an average of 15.2% of their body weight, vs. 2.6% with a placebo. In trials, weight loss was maintained as long as people remained on the medication. 

There’s also a higher Wegovy dose of 7.2 mg. Over 72 weeks, people taking this dose lost an average of 18.7% of their body weight, compared with 15.6% at the 2.4 mg dose and 3.9% on placebo. 

The daily pill works the same way as the injectable version, and its results fall in a similar range. In a trial, people taking the 25 mg tablet lost an average of 13.6% of their body weight over 64 weeks, compared with 2.2% on placebo. The pill and the injection have yet to be tested directly against each other, so the figures come from separate trials. 

Wegovy mimics glucagon-like peptide-1 (GLP-1), a hormone your gut releases when you eat. GLP-1 is one of the body’s own appetite regulators: It tells your brain when you’ve had enough, and it slows how fast food leaves your stomach. Semaglutide stays in your system far longer than the hormone you make naturally, so you feel fuller sooner and stay full longer. 

Wegovy doesn’t work mainly by burning fat or blocking calorie absorption. The weight loss comes from eating less. What the medication changes is how hard that is to do.

Yes, Wegovy can lower the risk of heart attack and stroke, and it's one of the FDA-approved Wegovy benefits. In people who already have heart disease and carry excess weight, the weekly injection lowered the risk of heart attack, stroke, or cardiovascular death by 20%.

That finding comes from a trial of more than 17,000 people aged 45 and older, all with existing heart disease but without diabetes. Over about 40 months, 6.5% of participants taking semaglutide had a major cardiovascular event, compared with 8.0% on placebo. 

Further analysis of the trial found no link between weight lost in the first 20 weeks and later cardiovascular events, and estimated that only about a third of the overall benefit came from reduced waist size. That suggests the injection could work on the heart and blood vessels beyond weight management. 

Wegovy may modestly improve cholesterol, too. In the same trial, Wegovy lowered triglycerides by about 15.6% relative to placebo, and LDL (“bad”) cholesterol by about 2.2%. Neither is an approved use on its own, but high LDL drives plaque buildup in arteries that can lead to heart attacks and strokes, the same events the trial measured. 

In 2024, the FDA approved the Wegovy injection for the reduction of cardiovascular risk in adults with heart disease who carry excess weight, the first obesity medication to receive that approval. The pill, approved in December 2025, covers the same use.

Yes, Wegovy can lower blood pressure, though the effect is modest. Across six trials in people without diabetes, semaglutide lowered systolic blood pressure (the top number in a reading) by an average of 4.83 mmHg.

The cardiovascular trial above found a similar effect: an average drop of 3.8 mmHg with semaglutide, compared with 0.5 mmHg on placebo.  

Most of the effect on blood pressure appears to come from weight loss itself. A pooled analysis of three trials estimated that weight change accounted for about 89% of the drop in systolic pressure. High blood pressure is one of the biggest risk factors for heart disease and stroke, so even a small reduction matters for your long-term risk. 

Wegovy isn’t a blood pressure medication, and doesn’t replace one. But if you’re already taking it for your weight or your heart, a drop in blood pressure can be a bonus on top. 

Yes, the Wegovy injection is approved to treat MASH. In August 2025, the FDA granted it accelerated approval to treat MASH in adults with moderate to advanced liver scarring, known as fibrosis. It isn’t approved once that scarring has progressed to cirrhosis, the most severe stage. 

MASH is the more serious form of fatty liver disease, and it’s closely tied to carrying excess weight: more than 60% of people with fatty liver disease also have obesity, diabetes, or both. Left untreated, MASH can progress to cirrhosis, liver failure, or liver cancer. Millions of US adults are thought to live with the condition. 

The trial behind the approval found that after 72 weeks on semaglutide, 62.9% of people saw their MASH resolve without their liver scarring getting worse, compared with 34.3% on placebo. Another 36.8% saw their liver scarring improve without their MASH getting worse, versus 22.4% on placebo. 

The Wegovy injection is the first GLP-1 medication approved for MASH, and only the second medication of any kind to get that approval.

Check for free

No, Ozempic and Wegovy don't have the same benefits. Ozempic and Wegovy are brand-name prescription drugs that share the same active ingredient, semaglutide. But the FDA has approved them for different uses, so their benefits only partly overlap.

The main Ozempic benefits focus on type 2 diabetes: better blood sugar control and a lower risk of further kidney decline in adults who also have chronic kidney disease. That kidney approval applies to the weekly injection. Ozempic also comes as a daily pill, approved for blood sugar control and heart risk reduction.

Both drugs are approved to lower cardiovascular risk, though for different groups. The Ozempic injection covers adults with type 2 diabetes and established heart disease, while Wegovy covers adults with heart disease who carry excess weight.

When it comes to dose, Ozempic's injection tops out at 2 mg per week, while Wegovy's injection goes up to 7.2 mg per week. Wegovy's higher doses are what carry its weight- management approval, which Ozempic doesn't have.

A healthcare provider can help you work out which medication and dose is right for you. Dosage should be discussed with a healthcare provider, not something to handle on your own.

Wegovy is best known for weight loss, and the trial data support that. But Wegovy’s benefits also cover heart and liver health, and each approval applies to a different group of people. Blood pressure can improve, too, though that isn't something Wegovy is prescribed for. Here’s what to know:

• Wegovy produces significant, sustained weight loss. Trial averages ran from about 14% on the daily pill to nearly 19% on the highest-dose injection, and the effect held up over two years in a longer trial.

• It lowers the risk of heart attack and stroke, but only for certain people. The 20% reduction applies to adults with heart disease who carry excess weight. Both the pill and the injection are approved for this.

• Only the injection treats MASH. It's approved for adults with MASH and moderate to advanced liver scarring who don't have cirrhosis, under an accelerated approval that still has to be confirmed in a longer trial.

• Wegovy also lowers blood pressure, though it isn't approved for that. Systolic readings fell by roughly 4–5 mmHg across trials, mostly due to weight loss.

• Wegovy and Ozempic aren't interchangeable. They share an active ingredient, but Ozempic's benefits focus on type 2 diabetes, with the injection adding kidney protection for people who have both type 2 diabetes and chronic kidney disease. Wegovy is approved for weight management.

Wegovy is a prescription medication, and whether it's right for you depends on your health history, your current medications, and your goals. Ro connects you with licensed healthcare providers who can help you decide if it's a good fit and talk you through Wegovy's safety profile and side effects of the pill or injection before you start.